Making a good drug better

What is it about?

This paper describes the activity of inhibitors in combination against Hepatitis c virus variants that are resistant to the NS5A inhibitor daclatasvir. The compounds by themselves are either not active or only weakly active against the variants, when combined they regain pico-molar potency.

Featured Image

Why is it important?

This study extends the previous study and demonstrates that two essentially inactive compounds can become active when combined.